14-Apr-2026
Mid-cap healthcare stocks with A grade EPS revisions ahead of earnings
Seeking Alpha News (Fri, 10-Apr 5:14 PM ET)
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results
Globe Newswire (Thu, 5-Feb 4:05 PM ET)
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 27-Jan 4:05 PM ET)
Globe Newswire (Thu, 22-Jan 4:05 PM ET)
Market Chameleon (Mon, 12-Jan 3:16 AM ET)
Market Chameleon (Mon, 15-Dec 4:26 AM ET)
clonoSEQ MRD Test Featured in 89 Abstracts at ASH 2025—Expanding Role in Blood Cancer Care
Market Chameleon (Mon, 24-Nov 4:17 AM ET)
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Adaptive Biotechnologies trades on the NASDAQ stock market under the symbol ADPT.
As of April 14, 2026, ADPT stock price climbed to $14.53 with 1,241,578 million shares trading.
ADPT has a beta of 1.44, meaning it tends to be more sensitive to market movements. ADPT has a correlation of 0.07 to the broad based SPY ETF.
ADPT has a market cap of $2.22 billion. This is considered a Mid Cap stock.
Last quarter Adaptive Biotechnologies reported $72 million in Revenue and -$.09 earnings per share. This beat revenue expectation by $11 million and exceeded earnings estimates by $.10.
In the last 3 years, ADPT traded as high as $20.76 and as low as $2.28.
The top ETF exchange traded funds that ADPT belongs to (by Net Assets): VTI, IWM, ARKG, VB, VXF.
ADPT has outperformed the market in the last year with a return of +85.8%, while the SPY ETF gained +30.2%. However, in the most recent history, ADPT shares have underperformed the stock market with its stock returning -19.5% in the last 3 month period and +4.7% for the last 2 week period, while SPY has returned +0.9% and +6.8%, respectively.
ADPT support price is $13.39 and resistance is $14.87 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADPT shares will trade within this expected range on the day.